FIELD: medicine.
SUBSTANCE: urine Bc1-2 content is determined in a patient by an immunoenzyme technique. If detecting the Bc1-2 level exceeding 2.0 ng/ml, ovarian cancer is diagnosed in the patient.
EFFECT: use of the method provides high-accuracy early detection of ovarian cancer.
15 cl, 12 dwg, 2 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HJURP PEPTIDES AND VACCINES CONTAINING THEM | 2011 |
|
RU2570560C2 |
| ANTIBODIES SPECIFIC TO TUMOUR AND USE THEREOF | 2011 |
|
RU2595403C2 |
| COMPOSITIONS AND METHODS OF TREATING AND DIAGNOSING CANCER-RESISTANT CANCER | 2015 |
|
RU2710735C2 |
| IDENTIFICATION OF TUMOUR-ASSOCIATED ANTIGENS FOR DIAGNOSTICS AND THERAPY | 2013 |
|
RU2644686C2 |
| COMPOSITIONS AND APPLICATION METHODS FOR DETECTING HE4a | 2011 |
|
RU2650778C2 |
| REPRESENTATIVE DIAGNOSIS | 2016 |
|
RU2743169C2 |
| COMPOSITION AND METHOD FOR DETECTING MALIGNANT NEOPLASTIC DISEASE | 2015 |
|
RU2678135C1 |
| COMBINATION THERAPY AND METHOD FOR ASSESSING RESISTANCE TO TREATMENT | 2011 |
|
RU2587053C2 |
| ALLOSTERIC ANTIBODIES AGAINST HUMAN HER3 NON COMPETITIVE FOR NEUREGULIN AND USE THEREOF | 2013 |
|
RU2704228C2 |
| METHOD FOR NEOPLASTIC DISEASE DETECTION ON THE BASIS OF SOLUBILISED PHYSIOLOGICAL SAMPLE | 2004 |
|
RU2405158C2 |
